Compare · BSX vs LMAT
BSX vs LMAT
Side-by-side comparison of Boston Scientific Corporation (BSX) and LeMaitre Vascular Inc. (LMAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and LMAT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 40.0x LMAT ($1.81B).
- BSX has been more active in the news (11 items in the past 4 weeks vs 5 for LMAT).
- BSX has more recent analyst coverage (25 ratings vs 17 for LMAT).
- Company
- Boston Scientific Corporation
- LeMaitre Vascular Inc.
- Price
- -
- -
- Market cap
- $72.26B
- $1.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2006
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 17
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
LeMaitre Vascular Inc.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
Latest LMAT
- LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
- Lemaitre Vascular downgraded by Barrington Research
- SEC Form 10-Q filed by LeMaitre Vascular Inc.
- LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- LeMaitre Q2 2026 Financial Results
- LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
- SEC Form 4 filed by Director Jasinski Lawrence J
- SEC Form 4 filed by Director O'Connor John James
- SEC Form 4 filed by Director Roush John A
- SEC Form 4 filed by Director Shadan Martha